Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + ipilimumab vs nivolumab monotherapy in advanced renal cell carcinoma
NCT03873402Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2019
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 3 trial of ipilimumab in renal cell carcinoma (RCC), sponsored by Bristol Myers Squibb. Started Jun 2019; status: active, not recruiting.
02
Drugs
ipilimumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03873402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03873402.